Novartis Ag (NVS) Receivables (2009 - 2026)

Novartis Ag has disclosed Receivables across 18 years of filings, most recently posting $9.6 billion for Q2 2026.

• In Q2 2026, Receivables rose 6.4% year-over-year to $9.6 billion; the TTM figure through Jun 2026 stood at $9.6 billion (up 6.4% YoY), while the FY2025 annual figure was $8.9 billion, up 2.13% from the prior year.
• Receivables came in at $9.6 billion for Q2 2026 at Novartis Ag, up from $9.4 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $9.6 billion in Q2 2026 to a low of $6.8 billion in Q3 2023.
• Average Receivables over 5 years is $8.6 billion, with a median of $8.7 billion recorded in 2022.
• Year-over-year, Receivables slipped 19.03% in 2023 and climbed 16.82% in 2024.
• Over 5 years, Receivables stood at $9.0 billion in 2022, then slipped by 7.37% to $8.4 billion in 2023, then gained by 4.69% to $8.8 billion in 2024, then grew by 2.13% to $8.9 billion in 2025, then climbed by 7.82% to $9.6 billion in 2026.
• Per Business Quant data, the three most recent Receivables figures were $9.6 billion in Q2 2026, $9.4 billion in Q1 2026, and $8.9 billion in Q4 2025.